Skip to main content
Signal8
Launch Terminal
Minai-Azary Jennifer Lynn profile photo

Jennifer Lynn Minai-Azary

CIK: 0001844398

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Context Therapeutics Inc. logo
CNTX

Context Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Context Therapeutics Inc. logo
    CNTX

    Context Therapeutics Inc.

    Feb 19, 2026
    Award(A)

    Stock Option (right to buy)

    Direct
    275K shares-
  • Context Therapeutics Inc. logo
    CNTX

    Context Therapeutics Inc.

    Jun 6, 2025
    Purchase(P)
    Direct
    40K shares at avg. $0.64$25K
  • Context Therapeutics Inc. logo
    CNTX

    Context Therapeutics Inc.

    Feb 13, 2025
    Award(A)

    Stock Option (right to buy)

    Direct
    371.8K shares-

1-3 of 3

About Minai-Azary Jennifer Lynn

Minai-Azary Jennifer Lynn (SEC CIK 0001844398) files insider reports with the SEC as Chief Financial Officer of Context Therapeutics Inc. (CNTX).

Signal8 holds 3 ownership filings by Minai-Azary Jennifer Lynn, all Form 4s, filed between Feb 14, 2025 and Feb 23, 2026. Those filings report 3 transactions, from Feb 13, 2025 to Feb 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Minai-Azary Jennifer Lynn's filings is in PHILADELPHIA, PA.

Recent filings by Minai-Azary Jennifer Lynn

  • Feb 19, 2026: Grant or award of CNTX derivative securities (Form 4, code A).
  • Jun 6, 2025: Open-market purchase of CNTX shares (Form 4, code P).
  • Feb 13, 2025: Grant or award of CNTX derivative securities (Form 4, code A).

Other insiders filing for Context Therapeutics Inc. (CNTX)

How to read Form 4 transaction codes